TY - JOUR T1 - Baseline Cardiometabolic Profiles and SARS-CoV-2 Risk in the UK Biobank JF - medRxiv DO - 10.1101/2020.07.25.20161091 SP - 2020.07.25.20161091 AU - Ryan J. Scalsky AU - Karan Desai AU - Yi-Ju Chen AU - Jeffery R. O’Connell AU - James A. Perry AU - Charles C. Hong Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/29/2020.07.25.20161091.abstract N2 - Background SARS-CoV-2 is a rapidly spreading coronavirus with a high incidence of severe upper respiratory infection that first presented in Wuhan, China in December 2019. Many factors have been identified as risk factors for SARS-CoV-2, with much attention being paid to body mass index (BMI), but little investigation has been done to investigate dysregulation of lipid profiles and diabetes, which are often comorbid in high BMI patients.Objective This study seeks to describe the impact of BMI, HDL, LDL, ApoA, ApoB, triglycerides, hemoglobin A1c (HbA1c), diabetes, alcohol and red wine intake on SARS-CoV-2 risk in UK Biobank (UKB) study participants.Methods We examined the effect of BMI, lipid profiles, diabetes and alcohol intake on the risk of testing positive for SARS-Cov-2 among 9,005 UKB participants tested for SARS-CoV-2 from March 16 through June 29, 2020. Logistic regression was performed on the target variables controlling for age, sex and ancestry.Results BMI, Type II diabetes and HbA1c were associated with increased SARS-CoV-2 risk (p < 0.05) while HDL and ApoA were associated with decreased risk (p < 0.001). Additionally, red wine intake was associated with reduced SARS-CoV-2 risk (p < 0.05). LDL, ApoB and triglyceride levels were not found to be significantly associated with increased risk.Conclusion Elevated HDL and ApoA levels and alcohol intake, specifically red wine intake, were associated with reduced risk of testing positive for SARS-CoV-2, while type II diabetes and HbA1c were associated with increased risk. The effects of alcohol, type II diabetes and HbA1c levels may be indirect, mediated in part through regulation of HDL levels. In summary, our study corroborates the emerging picture that high HDL levels may confer protection against SARS-CoV-2.HighlightsIncreases in HDL is associated with reduced risk of testing positive for SARS-CoV-2.Type II diabetes and hemoglobin A1C levels were associated with elevated risk of testing positive for SARS-CoV-2, but this effect was abrogated when controlling for HDL.Alcohol intake, specifically red wine intake, is associated with reduced risk of testing positive for SARS-CoV-2, though this effect may in part be moderated by HDL.LDL and Triglycerides were not associated with increased risk of testing positive for SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was conducted using the UK Biobank Resource under Application Number 49852. This work was supported by 5T32GM092237-10 to RS, NIGMS R01GM118557, NHLBI R01HL135129 to CCH, and NHLBI 1U01HL137181 to JP. The funders had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; or decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB # for this study is HF-00088022 Phenome-wide association study (PheWAS) using UK Biobank Database. It was deemed NOT HUMAN RESEARCH.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this research was downloaded from the UK Biobank Resource under Application Number 49852. Copies of the data may be obtained from the UK Biobank Resource. The data access procedure is provided on their website. (https://www.ukbiobank.ac.uk/wp-content/uploads/2012/09/Access-Procedures-2011-1.pdf) ER -